Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib

Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer

(2015) Hideki Terai et al.   ACS Chemical Biology

FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers

(2015) F. Goke et al.   CLINICAL CANCER RESEARCH

Downregulation of discoidin domain receptor 2 decreases tumor growth of hepatocellular carcinoma

(2015) Joong-Won Park et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma

(2015) Matthew L. Hedberg et al.   JOURNAL OF CLINICAL INVESTIGATION

Overexpression of DDR2 contributes to cell invasion and migration in head and neck squamous cell carcinoma

(2014) Jinke Xu et al.   CANCER BIOLOGY & THERAPY

Adaptive Responses to Dasatinib-Treated Lung Squamous Cell Cancer Cells Harboring DDR2 Mutations

(2014) Y. Bai et al.   CANCER RESEARCH

Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas

(2014) Tanguy Y. Seiwert et al.   CLINICAL CANCER RESEARCH

US trade rep is pressing Indian government to forbid production of generic cancer drug, consortium says

(2014) D. Cohen   BMJ-British Medical Journal

Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial

(2013) Renato G. Martins et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung

(2013) Andrew M. Brunner et al.   Journal of Thoracic Oncology

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

(2013) Jan B Vermorken et al.   LANCET ONCOLOGY

Increased expression of discoidin domain receptor 2 (DDR2): a novel independent prognostic marker of worse outcome in breast cancer patients

(2013) Tingting Ren et al.   MEDICAL ONCOLOGY

Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck

(2013) Friederike Göke et al.   MODERN PATHOLOGY

Acquired Resistance to Dasatinib in Lung Cancer Cell Lines Conferred by DDR2 Gatekeeper Mutation and NF1 Loss

(2013) E. M. Beauchamp et al.   MOLECULAR CANCER THERAPEUTICS

The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis

(2013) Kun Zhang et al.   NATURE CELL BIOLOGY

Zebrafish xenografts as a tool for in vivo studies on human cancer

(2012) Martina Konantz et al.   Annals of the New York Academy of Sciences

Discoidin Domain Receptors Promote α1β1- and α2β1-Integrin Mediated Cell Adhesion to Collagen by Enhancing Integrin Activation

(2012) Huifang Xu et al.   PLoS One

Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile

(2011) Ardian Latifi et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer

(2011) Theresia Wilbertz et al.   MODERN PATHOLOGY

Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

(2011) Peter S. Hammerman et al.   Cancer Discovery

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma

(2010) Heather D. Brooks et al.   CANCER

Cell Signaling by Receptor Tyrosine Kinases

(2010) Mark A. Lemmon et al.   CELL

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma

(2009) T. Y. Seiwert et al.   CANCER RESEARCH

Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib

(2008) Elizabeth Day et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Recent advances in Oral Oncology 2007: Epidemiology, aetiopathogenesis, diagnosis and prognostication

(2008) Jose V. Bagan et al.   ORAL ONCOLOGY

Upregulation of discoidin domain receptor 2 in nasopharyngeal carcinoma

(2007) Huey-Huey Chua et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK